Status:
ENROLLING_BY_INVITATION
Genome Sequencing in the Intensive Care Unit Population
Lead Sponsor:
Jerry Vockley, MD, PhD
Conditions:
Infant, Newborn, Disease
Genetic Disease
Eligibility:
All Genders
Up to 1 years
Phase:
NA
Brief Summary
The purpose of this study is to understand how the use of whole genome sequencing (WGS) may be able to increase the speed with which a diagnosis is made for patients in an intensive care unit populati...
Detailed Description
This is an observational study to understand if the use of whole genome sequencing (WGS) increases the speed to diagnosis and how clinical management is changed in an intensive care population of neon...
Eligibility Criteria
Inclusion
- Neonates: In order to be approached to participate, a neonate must meet all of the following criteria:
- Greater than 24 weeks gestational age
- Birth weight greater than 600 grams
- Admitted to the intensive care unit at UPMC Children's Hospital (CHP) and/or Magee Women's Hospital
- Possibility of a genetic disorder based on signs, symptoms, and laboratory values triggering a formal clinical medical genetics consult by the clinical care team.
- Triaged by PI or attending co-investigators and prioritized to introduction of this research study based on patient-specific clinical concerns
- Documented informed consent from parent/guardian
- Parents: Parent of a neonate who meets the above inclusion criteria and who has been consented to participate in the study.
- Siblings: Siblings of a neonate who meets the above inclusion criteria and who has been consented to participate in the study. Siblings will only be recruited if their participation has been determined to be essential to the accurate interpretation of the neonate's genetic studies.
- Historical Controls: Individuals who have been evaluated by Medical Genetics within the last 24 months and who meet the criteria for matched controls as defined by propensity score matching.
Exclusion
- Neonates: An individual who meets any of the following criteria will be excluded from participating in this study:
- Has a known etiologic diagnosis (e.g. prenatal testing)
- Has a major congenital anomaly (renal, cardiac, hepatic, neurological, or pulmonary malformations) associated with a chromosomal anomaly detected on prenatal testing (e.g. ultrasound, genetic testing)
- Sequencing sent after birth for any other reason than the genetics consult that triggers the study
- Presence of documented significant congenital infection (e.g. congenital cytomegalovirus)
- Parents:
- Is not the biological parent of the identified neonate
- There is no exclusion for parent participation. If the parent is less than 18 years of age, however, these individuals will be asked to assent to the study and their parent(s) will be asked to provide permission/consent for the minor parent's participation
- Having had previous genetic testing does not exclude the parent from participating in this study.
- Siblings:
- Is not a biological sibling of a neonate who meets the inclusion criteria
- Is not require for accurate interpretation of neonate results
- Having had previous genetic testing does not exclude the sibling from participating in this study.
- Historical Control: Has not been seen within the past 24 months and/or does not meet the criteria for matched control as defined by propensity score matching. Part of this matching requires that the historical control be matched to a study participant based on age, thus they will be selected based on all matching criteria and will be excluded if they do not meet the criteria, including age.
Key Trial Info
Start Date :
July 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04848090
Start Date
July 13 2020
End Date
June 1 2027
Last Update
January 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15224